nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Pseudoephedrine—NFATC1—osteoporosis	0.0158	0.768	CrCbGaD
Dextroamphetamine—Lacosamide—CA2—osteoporosis	0.00291	0.141	CrCbGaD
Dextroamphetamine—Pseudoephedrine—TNF—osteoporosis	0.00186	0.0902	CrCbGaD
Dextroamphetamine—Somnolence—Calcitriol—osteoporosis	0.00182	0.00215	CcSEcCtD
Dextroamphetamine—Decreased appetite—Ibandronate—osteoporosis	0.00182	0.00215	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00181	0.00213	CcSEcCtD
Dextroamphetamine—Depression—Estradiol—osteoporosis	0.00181	0.00213	CcSEcCtD
Dextroamphetamine—Fatigue—Ibandronate—osteoporosis	0.00181	0.00213	CcSEcCtD
Dextroamphetamine—Chest pain—Risedronate—osteoporosis	0.0018	0.00213	CcSEcCtD
Dextroamphetamine—Anxiety—Risedronate—osteoporosis	0.00179	0.00212	CcSEcCtD
Dextroamphetamine—Constipation—Ibandronate—osteoporosis	0.00179	0.00211	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Estropipate—osteoporosis	0.00179	0.00211	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Estradiol—osteoporosis	0.00179	0.00211	CcSEcCtD
Dextroamphetamine—Decreased appetite—Calcitriol—osteoporosis	0.00178	0.0021	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Estradiol—osteoporosis	0.00178	0.0021	CcSEcCtD
Dextroamphetamine—Dry mouth—Risedronate—osteoporosis	0.00176	0.00208	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Estradiol—osteoporosis	0.00176	0.00208	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Alendronate—osteoporosis	0.00176	0.00208	CcSEcCtD
Dextroamphetamine—Infection—Ethinyl Estradiol—osteoporosis	0.00176	0.00208	CcSEcCtD
Dextroamphetamine—Constipation—Calcitriol—osteoporosis	0.00175	0.00207	CcSEcCtD
Dextroamphetamine—Convulsion—Pamidronate—osteoporosis	0.00174	0.00206	CcSEcCtD
Dextroamphetamine—Hypertension—Pamidronate—osteoporosis	0.00174	0.00205	CcSEcCtD
Dextroamphetamine—Tension—Conjugated Estrogens—osteoporosis	0.00174	0.00205	CcSEcCtD
Dextroamphetamine—Urticaria—Estropipate—osteoporosis	0.00174	0.00205	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Raloxifene—osteoporosis	0.00173	0.00204	CcSEcCtD
Dextroamphetamine—Diarrhoea—Etidronic acid—osteoporosis	0.00173	0.00204	CcSEcCtD
Dextroamphetamine—Body temperature increased—Estropipate—osteoporosis	0.00173	0.00204	CcSEcCtD
Dextroamphetamine—Abdominal pain—Estropipate—osteoporosis	0.00173	0.00204	CcSEcCtD
Dextroamphetamine—Tremor—Zoledronate—osteoporosis	0.00172	0.00203	CcSEcCtD
Dextroamphetamine—Nervousness—Conjugated Estrogens—osteoporosis	0.00172	0.00203	CcSEcCtD
Dextroamphetamine—Infection—Risedronate—osteoporosis	0.00172	0.00202	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Ibandronate—osteoporosis	0.00171	0.00202	CcSEcCtD
Dextroamphetamine—Urticaria—Alendronate—osteoporosis	0.00171	0.00202	CcSEcCtD
Dextroamphetamine—Anxiety—Pamidronate—osteoporosis	0.00171	0.00201	CcSEcCtD
Dextroamphetamine—Abdominal pain—Alendronate—osteoporosis	0.0017	0.00201	CcSEcCtD
Dextroamphetamine—Body temperature increased—Alendronate—osteoporosis	0.0017	0.00201	CcSEcCtD
Dextroamphetamine—Agitation—Zoledronate—osteoporosis	0.00169	0.00199	CcSEcCtD
Dextroamphetamine—Angioedema—Zoledronate—osteoporosis	0.00168	0.00198	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Calcitriol—osteoporosis	0.00168	0.00198	CcSEcCtD
Dextroamphetamine—Body temperature increased—Raloxifene—osteoporosis	0.00167	0.00197	CcSEcCtD
Dextroamphetamine—Abdominal pain—Raloxifene—osteoporosis	0.00167	0.00197	CcSEcCtD
Dextroamphetamine—Urticaria—Ibandronate—osteoporosis	0.00166	0.00196	CcSEcCtD
Dextroamphetamine—Body temperature increased—Ibandronate—osteoporosis	0.00166	0.00195	CcSEcCtD
Dextroamphetamine—Abdominal pain—Ibandronate—osteoporosis	0.00166	0.00195	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Pamidronate—osteoporosis	0.00164	0.00194	CcSEcCtD
Dextroamphetamine—Infection—Pamidronate—osteoporosis	0.00163	0.00192	CcSEcCtD
Dextroamphetamine—Urticaria—Calcitriol—osteoporosis	0.00163	0.00192	CcSEcCtD
Dextroamphetamine—Palpitations—Zoledronate—osteoporosis	0.00162	0.00192	CcSEcCtD
Dextroamphetamine—Abdominal pain—Calcitriol—osteoporosis	0.00162	0.00191	CcSEcCtD
Dextroamphetamine—Body temperature increased—Calcitriol—osteoporosis	0.00162	0.00191	CcSEcCtD
Dextroamphetamine—Angioedema—Conjugated Estrogens—osteoporosis	0.00162	0.00191	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Estropipate—osteoporosis	0.00161	0.0019	CcSEcCtD
Dextroamphetamine—Vomiting—Etidronic acid—osteoporosis	0.00161	0.00189	CcSEcCtD
Dextroamphetamine—Tachycardia—Pamidronate—osteoporosis	0.0016	0.00189	CcSEcCtD
Dextroamphetamine—Rash—Etidronic acid—osteoporosis	0.00159	0.00188	CcSEcCtD
Dextroamphetamine—Convulsion—Zoledronate—osteoporosis	0.00159	0.00188	CcSEcCtD
Dextroamphetamine—Dermatitis—Etidronic acid—osteoporosis	0.00159	0.00188	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Pamidronate—osteoporosis	0.00159	0.00187	CcSEcCtD
Dextroamphetamine—Hypertension—Zoledronate—osteoporosis	0.00159	0.00187	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Alendronate—osteoporosis	0.00159	0.00187	CcSEcCtD
Dextroamphetamine—Headache—Etidronic acid—osteoporosis	0.00158	0.00187	CcSEcCtD
Dextroamphetamine—Asthenia—Estropipate—osteoporosis	0.00157	0.00185	CcSEcCtD
Dextroamphetamine—Anorexia—Pamidronate—osteoporosis	0.00156	0.00185	CcSEcCtD
Dextroamphetamine—Chest pain—Zoledronate—osteoporosis	0.00156	0.00185	CcSEcCtD
Dextroamphetamine—Palpitations—Conjugated Estrogens—osteoporosis	0.00156	0.00184	CcSEcCtD
Dextroamphetamine—Insomnia—Risedronate—osteoporosis	0.00156	0.00184	CcSEcCtD
Dextroamphetamine—Anxiety—Zoledronate—osteoporosis	0.00156	0.00184	CcSEcCtD
Dextroamphetamine—Asthenia—Alendronate—osteoporosis	0.00154	0.00182	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Ibandronate—osteoporosis	0.00154	0.00182	CcSEcCtD
Dextroamphetamine—Dyspnoea—Risedronate—osteoporosis	0.00154	0.00182	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Estradiol—osteoporosis	0.00154	0.00181	CcSEcCtD
Dextroamphetamine—Convulsion—Conjugated Estrogens—osteoporosis	0.00153	0.00181	CcSEcCtD
Dextroamphetamine—Dry mouth—Zoledronate—osteoporosis	0.00153	0.0018	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00153	0.0018	CcSEcCtD
Dextroamphetamine—Fatigue—Ethinyl Estradiol—osteoporosis	0.00153	0.0018	CcSEcCtD
Dextroamphetamine—Dyspepsia—Risedronate—osteoporosis	0.00152	0.00179	CcSEcCtD
Dextroamphetamine—Constipation—Ethinyl Estradiol—osteoporosis	0.00151	0.00179	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Calcitriol—osteoporosis	0.00151	0.00178	CcSEcCtD
Dextroamphetamine—Chest pain—Conjugated Estrogens—osteoporosis	0.00151	0.00178	CcSEcCtD
Dextroamphetamine—Asthenia—Ibandronate—osteoporosis	0.0015	0.00177	CcSEcCtD
Dextroamphetamine—Anxiety—Conjugated Estrogens—osteoporosis	0.0015	0.00177	CcSEcCtD
Dextroamphetamine—Nausea—Etidronic acid—osteoporosis	0.0015	0.00177	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Zoledronate—osteoporosis	0.0015	0.00177	CcSEcCtD
Dextroamphetamine—Diarrhoea—Estropipate—osteoporosis	0.00149	0.00176	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00149	0.00176	CcSEcCtD
Dextroamphetamine—Infection—Zoledronate—osteoporosis	0.00149	0.00176	CcSEcCtD
Dextroamphetamine—Fatigue—Risedronate—osteoporosis	0.00149	0.00176	CcSEcCtD
Dextroamphetamine—Insomnia—Pamidronate—osteoporosis	0.00148	0.00175	CcSEcCtD
Dextroamphetamine—Constipation—Risedronate—osteoporosis	0.00148	0.00174	CcSEcCtD
Dextroamphetamine—Diarrhoea—Alendronate—osteoporosis	0.00147	0.00174	CcSEcCtD
Dextroamphetamine—Asthenia—Calcitriol—osteoporosis	0.00147	0.00174	CcSEcCtD
Dextroamphetamine—Dyspnoea—Pamidronate—osteoporosis	0.00146	0.00173	CcSEcCtD
Dextroamphetamine—Tachycardia—Zoledronate—osteoporosis	0.00146	0.00173	CcSEcCtD
Dextroamphetamine—Somnolence—Pamidronate—osteoporosis	0.00146	0.00172	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Zoledronate—osteoporosis	0.00145	0.00171	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00145	0.00171	CcSEcCtD
Dextroamphetamine—Diarrhoea—Raloxifene—osteoporosis	0.00145	0.00171	CcSEcCtD
Dextroamphetamine—Dyspepsia—Pamidronate—osteoporosis	0.00144	0.0017	CcSEcCtD
Dextroamphetamine—Dizziness—Estropipate—osteoporosis	0.00144	0.0017	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00144	0.0017	CcSEcCtD
Dextroamphetamine—Infection—Conjugated Estrogens—osteoporosis	0.00143	0.00169	CcSEcCtD
Dextroamphetamine—Diarrhoea—Ibandronate—osteoporosis	0.00143	0.00169	CcSEcCtD
Dextroamphetamine—Anorexia—Zoledronate—osteoporosis	0.00143	0.00169	CcSEcCtD
Dextroamphetamine—Decreased appetite—Pamidronate—osteoporosis	0.00143	0.00168	CcSEcCtD
Dextroamphetamine—Dizziness—Alendronate—osteoporosis	0.00142	0.00168	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00142	0.00167	CcSEcCtD
Dextroamphetamine—Fatigue—Pamidronate—osteoporosis	0.00141	0.00167	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Risedronate—osteoporosis	0.00141	0.00167	CcSEcCtD
Dextroamphetamine—Tachycardia—Conjugated Estrogens—osteoporosis	0.00141	0.00166	CcSEcCtD
Dextroamphetamine—Urticaria—Ethinyl Estradiol—osteoporosis	0.00141	0.00166	CcSEcCtD
Dextroamphetamine—Constipation—Pamidronate—osteoporosis	0.0014	0.00166	CcSEcCtD
Dextroamphetamine—Diarrhoea—Calcitriol—osteoporosis	0.0014	0.00166	CcSEcCtD
Dextroamphetamine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.0014	0.00165	CcSEcCtD
Dextroamphetamine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.0014	0.00165	CcSEcCtD
Dextroamphetamine—Dizziness—Raloxifene—osteoporosis	0.0014	0.00165	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.0014	0.00165	CcSEcCtD
Dextroamphetamine—Tension—Estradiol—osteoporosis	0.00139	0.00164	CcSEcCtD
Dextroamphetamine—Vomiting—Estropipate—osteoporosis	0.00139	0.00164	CcSEcCtD
Dextroamphetamine—Dizziness—Ibandronate—osteoporosis	0.00139	0.00163	CcSEcCtD
Dextroamphetamine—Rash—Estropipate—osteoporosis	0.00138	0.00163	CcSEcCtD
Dextroamphetamine—Dermatitis—Estropipate—osteoporosis	0.00138	0.00162	CcSEcCtD
Dextroamphetamine—Anorexia—Conjugated Estrogens—osteoporosis	0.00138	0.00162	CcSEcCtD
Dextroamphetamine—Nervousness—Estradiol—osteoporosis	0.00137	0.00162	CcSEcCtD
Dextroamphetamine—Urticaria—Risedronate—osteoporosis	0.00137	0.00162	CcSEcCtD
Dextroamphetamine—Headache—Estropipate—osteoporosis	0.00137	0.00161	CcSEcCtD
Dextroamphetamine—Vomiting—Alendronate—osteoporosis	0.00137	0.00161	CcSEcCtD
Dextroamphetamine—Body temperature increased—Risedronate—osteoporosis	0.00136	0.00161	CcSEcCtD
Dextroamphetamine—Abdominal pain—Risedronate—osteoporosis	0.00136	0.00161	CcSEcCtD
Dextroamphetamine—Rash—Alendronate—osteoporosis	0.00136	0.0016	CcSEcCtD
Dextroamphetamine—Insomnia—Zoledronate—osteoporosis	0.00136	0.0016	CcSEcCtD
Dextroamphetamine—Dermatitis—Alendronate—osteoporosis	0.00136	0.0016	CcSEcCtD
Dextroamphetamine—Headache—Alendronate—osteoporosis	0.00135	0.00159	CcSEcCtD
Dextroamphetamine—Vomiting—Raloxifene—osteoporosis	0.00135	0.00159	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Pamidronate—osteoporosis	0.00134	0.00158	CcSEcCtD
Dextroamphetamine—Dyspnoea—Zoledronate—osteoporosis	0.00134	0.00158	CcSEcCtD
Dextroamphetamine—Rash—Raloxifene—osteoporosis	0.00133	0.00157	CcSEcCtD
Dextroamphetamine—Dermatitis—Raloxifene—osteoporosis	0.00133	0.00157	CcSEcCtD
Dextroamphetamine—Somnolence—Zoledronate—osteoporosis	0.00133	0.00157	CcSEcCtD
Dextroamphetamine—Vomiting—Ibandronate—osteoporosis	0.00133	0.00157	CcSEcCtD
Dextroamphetamine—Tremor—Estradiol—osteoporosis	0.00133	0.00156	CcSEcCtD
Dextroamphetamine—Headache—Raloxifene—osteoporosis	0.00133	0.00156	CcSEcCtD
Dextroamphetamine—Rash—Ibandronate—osteoporosis	0.00132	0.00156	CcSEcCtD
Dextroamphetamine—Dermatitis—Ibandronate—osteoporosis	0.00132	0.00156	CcSEcCtD
Dextroamphetamine—Dyspepsia—Zoledronate—osteoporosis	0.00132	0.00156	CcSEcCtD
Dextroamphetamine—Headache—Ibandronate—osteoporosis	0.00131	0.00155	CcSEcCtD
Dextroamphetamine—Insomnia—Conjugated Estrogens—osteoporosis	0.00131	0.00154	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.0013	0.00154	CcSEcCtD
Dextroamphetamine—Vomiting—Calcitriol—osteoporosis	0.0013	0.00154	CcSEcCtD
Dextroamphetamine—Decreased appetite—Zoledronate—osteoporosis	0.0013	0.00154	CcSEcCtD
Dextroamphetamine—Agitation—Estradiol—osteoporosis	0.0013	0.00154	CcSEcCtD
Dextroamphetamine—Nausea—Estropipate—osteoporosis	0.0013	0.00153	CcSEcCtD
Dextroamphetamine—Body temperature increased—Pamidronate—osteoporosis	0.0013	0.00153	CcSEcCtD
Dextroamphetamine—Abdominal pain—Pamidronate—osteoporosis	0.0013	0.00153	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00129	0.00153	CcSEcCtD
Dextroamphetamine—Angioedema—Estradiol—osteoporosis	0.00129	0.00153	CcSEcCtD
Dextroamphetamine—Rash—Calcitriol—osteoporosis	0.00129	0.00153	CcSEcCtD
Dextroamphetamine—Fatigue—Zoledronate—osteoporosis	0.00129	0.00153	CcSEcCtD
Dextroamphetamine—Dermatitis—Calcitriol—osteoporosis	0.00129	0.00152	CcSEcCtD
Dextroamphetamine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00129	0.00152	CcSEcCtD
Dextroamphetamine—Headache—Calcitriol—osteoporosis	0.00128	0.00152	CcSEcCtD
Dextroamphetamine—Somnolence—Conjugated Estrogens—osteoporosis	0.00128	0.00151	CcSEcCtD
Dextroamphetamine—Constipation—Zoledronate—osteoporosis	0.00128	0.00151	CcSEcCtD
Dextroamphetamine—Nausea—Alendronate—osteoporosis	0.00128	0.00151	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Risedronate—osteoporosis	0.00127	0.0015	CcSEcCtD
Dextroamphetamine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00127	0.0015	CcSEcCtD
Dextroamphetamine—Asthenia—Ethinyl Estradiol—osteoporosis	0.00127	0.0015	CcSEcCtD
Dextroamphetamine—Nausea—Raloxifene—osteoporosis	0.00126	0.00148	CcSEcCtD
Dextroamphetamine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00125	0.00148	CcSEcCtD
Dextroamphetamine—Palpitations—Estradiol—osteoporosis	0.00125	0.00148	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00125	0.00147	CcSEcCtD
Dextroamphetamine—Fatigue—Conjugated Estrogens—osteoporosis	0.00124	0.00147	CcSEcCtD
Dextroamphetamine—Nausea—Ibandronate—osteoporosis	0.00124	0.00147	CcSEcCtD
Dextroamphetamine—Asthenia—Risedronate—osteoporosis	0.00124	0.00146	CcSEcCtD
Dextroamphetamine—Constipation—Conjugated Estrogens—osteoporosis	0.00123	0.00146	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Zoledronate—osteoporosis	0.00123	0.00145	CcSEcCtD
Dextroamphetamine—Hypertension—Estradiol—osteoporosis	0.00122	0.00144	CcSEcCtD
Dextroamphetamine—Nausea—Calcitriol—osteoporosis	0.00122	0.00144	CcSEcCtD
Dextroamphetamine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00121	0.00143	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Pamidronate—osteoporosis	0.00121	0.00143	CcSEcCtD
Dextroamphetamine—Chest pain—Estradiol—osteoporosis	0.00121	0.00142	CcSEcCtD
Dextroamphetamine—Anxiety—Estradiol—osteoporosis	0.0012	0.00142	CcSEcCtD
Dextroamphetamine—Urticaria—Zoledronate—osteoporosis	0.00119	0.00141	CcSEcCtD
Dextroamphetamine—Abdominal pain—Zoledronate—osteoporosis	0.00118	0.0014	CcSEcCtD
Dextroamphetamine—Body temperature increased—Zoledronate—osteoporosis	0.00118	0.0014	CcSEcCtD
Dextroamphetamine—Diarrhoea—Risedronate—osteoporosis	0.00118	0.00139	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00118	0.00139	CcSEcCtD
Dextroamphetamine—Dry mouth—Estradiol—osteoporosis	0.00118	0.00139	CcSEcCtD
Dextroamphetamine—Asthenia—Pamidronate—osteoporosis	0.00118	0.00139	CcSEcCtD
Dextroamphetamine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00117	0.00138	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Estradiol—osteoporosis	0.00116	0.00136	CcSEcCtD
Dextroamphetamine—Infection—Estradiol—osteoporosis	0.00115	0.00135	CcSEcCtD
Dextroamphetamine—Urticaria—Conjugated Estrogens—osteoporosis	0.00115	0.00135	CcSEcCtD
Dextroamphetamine—Dizziness—Risedronate—osteoporosis	0.00114	0.00135	CcSEcCtD
Dextroamphetamine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00114	0.00135	CcSEcCtD
Dextroamphetamine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00114	0.00135	CcSEcCtD
Dextroamphetamine—Tachycardia—Estradiol—osteoporosis	0.00113	0.00133	CcSEcCtD
Dextroamphetamine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00113	0.00133	CcSEcCtD
Dextroamphetamine—Diarrhoea—Pamidronate—osteoporosis	0.00112	0.00133	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Estradiol—osteoporosis	0.00112	0.00132	CcSEcCtD
Dextroamphetamine—Rash—Ethinyl Estradiol—osteoporosis	0.00112	0.00132	CcSEcCtD
Dextroamphetamine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00112	0.00132	CcSEcCtD
Dextroamphetamine—Headache—Ethinyl Estradiol—osteoporosis	0.00111	0.00131	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Zoledronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Dextroamphetamine—Vomiting—Risedronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Dextroamphetamine—Rash—Risedronate—osteoporosis	0.00109	0.00128	CcSEcCtD
Dextroamphetamine—Dermatitis—Risedronate—osteoporosis	0.00109	0.00128	CcSEcCtD
Dextroamphetamine—Dizziness—Pamidronate—osteoporosis	0.00109	0.00128	CcSEcCtD
Dextroamphetamine—Headache—Risedronate—osteoporosis	0.00108	0.00128	CcSEcCtD
Dextroamphetamine—Asthenia—Zoledronate—osteoporosis	0.00108	0.00127	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00106	0.00125	CcSEcCtD
Dextroamphetamine—Nausea—Ethinyl Estradiol—osteoporosis	0.00105	0.00124	CcSEcCtD
Dextroamphetamine—Insomnia—Estradiol—osteoporosis	0.00104	0.00123	CcSEcCtD
Dextroamphetamine—Vomiting—Pamidronate—osteoporosis	0.00104	0.00123	CcSEcCtD
Dextroamphetamine—Asthenia—Conjugated Estrogens—osteoporosis	0.00104	0.00122	CcSEcCtD
Dextroamphetamine—Rash—Pamidronate—osteoporosis	0.00103	0.00122	CcSEcCtD
Dextroamphetamine—Dermatitis—Pamidronate—osteoporosis	0.00103	0.00122	CcSEcCtD
Dextroamphetamine—Dyspnoea—Estradiol—osteoporosis	0.00103	0.00122	CcSEcCtD
Dextroamphetamine—Headache—Pamidronate—osteoporosis	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Somnolence—Estradiol—osteoporosis	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Diarrhoea—Zoledronate—osteoporosis	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Nausea—Risedronate—osteoporosis	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Dyspepsia—Estradiol—osteoporosis	0.00102	0.0012	CcSEcCtD
Dextroamphetamine—Decreased appetite—Estradiol—osteoporosis	0.001	0.00119	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000997	0.00118	CcSEcCtD
Dextroamphetamine—Fatigue—Estradiol—osteoporosis	0.000996	0.00118	CcSEcCtD
Dextroamphetamine—Dizziness—Zoledronate—osteoporosis	0.000991	0.00117	CcSEcCtD
Dextroamphetamine—Constipation—Estradiol—osteoporosis	0.000988	0.00117	CcSEcCtD
Dextroamphetamine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000988	0.00117	CcSEcCtD
Dextroamphetamine—Nausea—Pamidronate—osteoporosis	0.000975	0.00115	CcSEcCtD
Dextroamphetamine—Dizziness—Conjugated Estrogens—osteoporosis	0.000954	0.00113	CcSEcCtD
Dextroamphetamine—Vomiting—Zoledronate—osteoporosis	0.000953	0.00112	CcSEcCtD
Dextroamphetamine—Rash—Zoledronate—osteoporosis	0.000945	0.00112	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Estradiol—osteoporosis	0.000945	0.00111	CcSEcCtD
Dextroamphetamine—Dermatitis—Zoledronate—osteoporosis	0.000944	0.00111	CcSEcCtD
Dextroamphetamine—Headache—Zoledronate—osteoporosis	0.000939	0.00111	CcSEcCtD
Dextroamphetamine—Vomiting—Conjugated Estrogens—osteoporosis	0.000918	0.00108	CcSEcCtD
Dextroamphetamine—Urticaria—Estradiol—osteoporosis	0.000918	0.00108	CcSEcCtD
Dextroamphetamine—Body temperature increased—Estradiol—osteoporosis	0.000913	0.00108	CcSEcCtD
Dextroamphetamine—Abdominal pain—Estradiol—osteoporosis	0.000913	0.00108	CcSEcCtD
Dextroamphetamine—Rash—Conjugated Estrogens—osteoporosis	0.00091	0.00107	CcSEcCtD
Dextroamphetamine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000909	0.00107	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—IL1B—osteoporosis	0.000906	0.00686	CbGpPWpGaD
Dextroamphetamine—Headache—Conjugated Estrogens—osteoporosis	0.000904	0.00107	CcSEcCtD
Dextroamphetamine—Nausea—Zoledronate—osteoporosis	0.00089	0.00105	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CALCA—osteoporosis	0.000874	0.00662	CbGpPWpGaD
Dextroamphetamine—Nausea—Conjugated Estrogens—osteoporosis	0.000857	0.00101	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Estradiol—osteoporosis	0.000851	0.001	CcSEcCtD
Dextroamphetamine—Asthenia—Estradiol—osteoporosis	0.000829	0.000978	CcSEcCtD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.000813	0.00616	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—MGLL—osteoporosis	0.000807	0.00612	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—IL1B—osteoporosis	0.000802	0.00608	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Estradiol—osteoporosis	0.00079	0.000933	CcSEcCtD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000787	0.00596	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SOST—osteoporosis	0.000765	0.00579	CbGpPWpGaD
Dextroamphetamine—Dizziness—Estradiol—osteoporosis	0.000764	0.000901	CcSEcCtD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—ADCY5—osteoporosis	0.000735	0.00557	CbGpPWpGaD
Dextroamphetamine—Vomiting—Estradiol—osteoporosis	0.000734	0.000867	CcSEcCtD
Dextroamphetamine—Rash—Estradiol—osteoporosis	0.000728	0.00086	CcSEcCtD
Dextroamphetamine—Dermatitis—Estradiol—osteoporosis	0.000728	0.000859	CcSEcCtD
Dextroamphetamine—Headache—Estradiol—osteoporosis	0.000724	0.000854	CcSEcCtD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.000722	0.00547	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CALCR—osteoporosis	0.000692	0.00524	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTH1R—osteoporosis	0.000692	0.00524	CbGpPWpGaD
Dextroamphetamine—Nausea—Estradiol—osteoporosis	0.000686	0.00081	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PTH—osteoporosis	0.000677	0.00513	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CNR2—osteoporosis	0.00066	0.005	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—osteoporosis	0.000657	0.00498	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—osteoporosis	0.000657	0.00497	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000625	0.00473	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTH—osteoporosis	0.000615	0.00466	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000601	0.00455	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CNR2—osteoporosis	0.000599	0.00454	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—LEP—osteoporosis	0.000593	0.00449	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—osteoporosis	0.000582	0.00441	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CALCR—osteoporosis	0.000577	0.00437	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTH1R—osteoporosis	0.000577	0.00437	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000569	0.00431	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—WNT1—osteoporosis	0.000564	0.00427	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PTHLH—osteoporosis	0.000561	0.00425	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MGLL—osteoporosis	0.000549	0.00416	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—LRP5—osteoporosis	0.000536	0.00406	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—LEP—osteoporosis	0.000527	0.00399	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—LRP6—osteoporosis	0.000513	0.00388	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTH1R—osteoporosis	0.000513	0.00388	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CALCR—osteoporosis	0.000513	0.00388	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.00051	0.00386	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTHLH—osteoporosis	0.00051	0.00386	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000503	0.00381	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—AGER—osteoporosis	0.000494	0.00374	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CALCA—osteoporosis	0.000494	0.00374	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—POMC—osteoporosis	0.000457	0.00346	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000453	0.00343	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CALCA—osteoporosis	0.000449	0.0034	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—AGER—osteoporosis	0.000438	0.00332	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—ADCY5—osteoporosis	0.000436	0.0033	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TLN1—osteoporosis	0.000433	0.00328	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000421	0.00319	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	0.000418	0.00316	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000413	0.00313	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	0.000412	0.00312	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000402	0.00305	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000388	0.00294	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000374	0.00283	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—P4HB—osteoporosis	0.000373	0.00283	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000373	0.00282	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTH—osteoporosis	0.000363	0.00275	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RAP1A—osteoporosis	0.000357	0.0027	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CNR2—osteoporosis	0.000354	0.00268	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADCY5—osteoporosis	0.000351	0.00266	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NFATC1—osteoporosis	0.000348	0.00264	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DKK1—osteoporosis	0.000346	0.00262	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000345	0.00261	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000339	0.00257	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—WNT1—osteoporosis	0.000333	0.00252	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000332	0.00252	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTH1R—osteoporosis	0.000326	0.00247	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CALCR—osteoporosis	0.000326	0.00247	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FGA—osteoporosis	0.000324	0.00245	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADCY5—osteoporosis	0.000319	0.00242	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000306	0.00232	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTH—osteoporosis	0.000303	0.0023	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTHLH—osteoporosis	0.000301	0.00228	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—BMP2—osteoporosis	0.000301	0.00228	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CALCR—osteoporosis	0.000296	0.00224	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTH1R—osteoporosis	0.000296	0.00224	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CNR2—osteoporosis	0.000295	0.00224	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FGB—osteoporosis	0.000295	0.00223	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CALCR—osteoporosis	0.00029	0.00219	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTH1R—osteoporosis	0.00029	0.00219	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PSMA5—osteoporosis	0.000284	0.00215	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PSMA2—osteoporosis	0.000284	0.00215	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—WNT1—osteoporosis	0.000278	0.0021	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTH—osteoporosis	0.000269	0.00204	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CALCA—osteoporosis	0.000265	0.00201	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CALCR—osteoporosis	0.000263	0.00199	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTH1R—osteoporosis	0.000263	0.00199	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CNR2—osteoporosis	0.000262	0.00199	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—ADCY5—osteoporosis	0.00026	0.00197	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—MGLL—osteoporosis	0.000259	0.00196	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—POMC—osteoporosis	0.000258	0.00196	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTHLH—osteoporosis	0.000251	0.0019	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000248	0.00188	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—WNT1—osteoporosis	0.000247	0.00187	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KL—osteoporosis	0.000241	0.00182	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MGLL—osteoporosis	0.000235	0.00178	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—POMC—osteoporosis	0.000235	0.00178	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000235	0.00178	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—MGLL—osteoporosis	0.00023	0.00174	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6R—osteoporosis	0.000229	0.00173	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTHLH—osteoporosis	0.000223	0.00169	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CALCA—osteoporosis	0.000221	0.00167	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	0.00022	0.00166	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	0.000216	0.00164	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—TGFB1—osteoporosis	0.000209	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MGLL—osteoporosis	0.000209	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.0002	0.00152	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CALCA—osteoporosis	0.000196	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SOST—osteoporosis	0.000193	0.00147	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADCY5—osteoporosis	0.000189	0.00143	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—TGFB1—osteoporosis	0.000185	0.0014	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SPP1—osteoporosis	0.000182	0.00138	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000178	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTH1R—osteoporosis	0.000175	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CALCR—osteoporosis	0.000175	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SOST—osteoporosis	0.000172	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTH—osteoporosis	0.000171	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CNR2—osteoporosis	0.000167	0.00126	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IRS2—osteoporosis	0.000165	0.00125	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—LEP—osteoporosis	0.000161	0.00122	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000158	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTH—osteoporosis	0.000156	0.00118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CALCR—osteoporosis	0.000155	0.00118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTH1R—osteoporosis	0.000155	0.00118	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ESR1—osteoporosis	0.000154	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTH—osteoporosis	0.000152	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000152	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CNR2—osteoporosis	0.000152	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CNR2—osteoporosis	0.000148	0.00112	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IRS1—osteoporosis	0.000144	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—WNT1—osteoporosis	0.000143	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTHLH—osteoporosis	0.000142	0.00108	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.00014	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MGLL—osteoporosis	0.000139	0.00105	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—POMC—osteoporosis	0.000139	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTH—osteoporosis	0.000138	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LRP5—osteoporosis	0.000136	0.00103	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6R—osteoporosis	0.000135	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000135	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CNR2—osteoporosis	0.000135	0.00102	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1—osteoporosis	0.000133	0.00101	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—POMC—osteoporosis	0.000132	0.000999	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LRP6—osteoporosis	0.00013	0.000983	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTHLH—osteoporosis	0.000129	0.000976	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—WNT1—osteoporosis	0.000127	0.000959	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTHLH—osteoporosis	0.000126	0.000955	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CALCA—osteoporosis	0.000125	0.000946	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PKM—osteoporosis	0.000124	0.000942	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FDPS—osteoporosis	0.000124	0.000942	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MGLL—osteoporosis	0.000123	0.000935	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LRP5—osteoporosis	0.00012	0.000913	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PGLS—osteoporosis	0.000118	0.000893	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPD2—osteoporosis	0.000118	0.000893	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—POMC—osteoporosis	0.000116	0.000876	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LRP6—osteoporosis	0.000115	0.000873	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTHLH—osteoporosis	0.000115	0.000867	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CALCA—osteoporosis	0.000113	0.00086	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CALCA—osteoporosis	0.000111	0.000841	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TLN1—osteoporosis	0.00011	0.00083	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PNP—osteoporosis	0.000108	0.000817	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ATIC—osteoporosis	0.000108	0.000817	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—POMC—osteoporosis	0.000103	0.000778	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—osteoporosis	0.000102	0.000772	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CALCA—osteoporosis	0.000101	0.000763	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TLN1—osteoporosis	9.73e-05	0.000737	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—P4HB—osteoporosis	9.45e-05	0.000715	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTH—osteoporosis	9.19e-05	0.000696	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—OXCT1—osteoporosis	9.17e-05	0.000695	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CA2—osteoporosis	9.17e-05	0.000695	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RAP1A—osteoporosis	9.03e-05	0.000684	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CNR2—osteoporosis	8.96e-05	0.000678	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MGLL—osteoporosis	8.94e-05	0.000677	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	8.92e-05	0.000675	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADCY5—osteoporosis	8.89e-05	0.000673	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NFATC1—osteoporosis	8.81e-05	0.000667	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DKK1—osteoporosis	8.74e-05	0.000662	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—WNT1—osteoporosis	8.42e-05	0.000638	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—P4HB—osteoporosis	8.39e-05	0.000636	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGA—osteoporosis	8.19e-05	0.00062	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTH—osteoporosis	8.16e-05	0.000618	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADCY5—osteoporosis	8.07e-05	0.000611	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RAP1A—osteoporosis	8.02e-05	0.000608	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—osteoporosis	8.02e-05	0.000607	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TGFB1—osteoporosis	8e-05	0.000606	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CNR2—osteoporosis	7.96e-05	0.000602	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	7.92e-05	0.0006	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADCY5—osteoporosis	7.9e-05	0.000598	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NFATC1—osteoporosis	7.83e-05	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DKK1—osteoporosis	7.76e-05	0.000588	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTHLH—osteoporosis	7.62e-05	0.000577	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BMP2—osteoporosis	7.62e-05	0.000577	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—IDH2—osteoporosis	7.6e-05	0.000576	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—WNT1—osteoporosis	7.48e-05	0.000566	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGB—osteoporosis	7.45e-05	0.000564	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGA—osteoporosis	7.28e-05	0.000551	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSMA2—osteoporosis	7.19e-05	0.000545	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSMA5—osteoporosis	7.19e-05	0.000545	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADCY5—osteoporosis	7.17e-05	0.000543	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP27A1—osteoporosis	7.15e-05	0.000541	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ACP5—osteoporosis	6.95e-05	0.000526	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BMP2—osteoporosis	6.76e-05	0.000512	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTHLH—osteoporosis	6.76e-05	0.000512	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CALCA—osteoporosis	6.7e-05	0.000508	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGB—osteoporosis	6.62e-05	0.000501	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—POMC—osteoporosis	6.54e-05	0.000495	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPI1—osteoporosis	6.46e-05	0.000489	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	6.39e-05	0.000484	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	6.39e-05	0.000484	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KL—osteoporosis	6.09e-05	0.000461	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—P4HB—osteoporosis	6.08e-05	0.00046	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—osteoporosis	6.03e-05	0.000456	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GAPDH—osteoporosis	5.96e-05	0.000452	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CALCA—osteoporosis	5.96e-05	0.000451	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—POMC—osteoporosis	5.94e-05	0.00045	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—RAP1A—osteoporosis	5.81e-05	0.00044	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	5.81e-05	0.00044	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6R—osteoporosis	5.79e-05	0.000439	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KL—osteoporosis	5.41e-05	0.00041	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—POMC—osteoporosis	5.27e-05	0.000399	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	5.15e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADCY5—osteoporosis	4.77e-05	0.000361	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO1—osteoporosis	4.7e-05	0.000356	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PSMA2—osteoporosis	4.63e-05	0.00035	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PSMA5—osteoporosis	4.63e-05	0.00035	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SPP1—osteoporosis	4.61e-05	0.000349	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	4.24e-05	0.000321	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IRS2—osteoporosis	4.17e-05	0.000316	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SPP1—osteoporosis	4.1e-05	0.00031	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LEP—osteoporosis	4.08e-05	0.000309	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—osteoporosis	3.9e-05	0.000295	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.75e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IRS2—osteoporosis	3.71e-05	0.000281	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IRS1—osteoporosis	3.64e-05	0.000276	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LEP—osteoporosis	3.63e-05	0.000275	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—POMC—osteoporosis	3.51e-05	0.000266	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—osteoporosis	3.46e-05	0.000262	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6R—osteoporosis	3.42e-05	0.000259	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—osteoporosis	3.37e-05	0.000256	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IRS1—osteoporosis	3.24e-05	0.000245	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—POMC—osteoporosis	3.12e-05	0.000236	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADCY5—osteoporosis	3.07e-05	0.000232	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—osteoporosis	3.06e-05	0.000231	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6R—osteoporosis	3.04e-05	0.00023	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—osteoporosis	3e-05	0.000227	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—osteoporosis	2.82e-05	0.000214	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—osteoporosis	2.58e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—osteoporosis	2.29e-05	0.000174	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—POMC—osteoporosis	2.26e-05	0.000171	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—osteoporosis	2.03e-05	0.000154	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	2.02e-05	0.000153	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—osteoporosis	1.8e-05	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	1.8e-05	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—osteoporosis	1.52e-05	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—osteoporosis	1.35e-05	0.000103	CbGpPWpGaD
